A Reading and Discussion with George Estreich

George Estreich discusses his most recent book Fables and Futures, inspired by his daughter Laura. Estreich goes beyond the personal to describe the ways that genetic technologies affect society and the stories the promoters of such technologies tell about them. The event took place on May 1, 2019 at the San Francisco Public Library.

Assisted Reproduction

Reproductive Futures: The Promises and Pitfalls of In-Vitro Gametogenesis

By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024

Aggregated News

In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...

Assisted Reproduction

Serving Two Masters: Trump Team’s Tensions on Reproductive Politics

By Pete Shanks | 12.16.2024

Biopolitical Times

^{Image by Mohamed Hassan from Pixabay}

It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.

On the one hand, consider “the conservative blueprint for a second Trump administration.”

The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...

Assisted Reproduction

An I.V.F. Mix-Up, a Shocking Discovery and an Unbearable Choice

By Susan Dominus, The New York Times | 11.30.2024

Aggregated News

In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...

Assisted Reproduction

FDA probes blood cancer risk from Bluebird’s gene therapy, weighs regulatory action

By Christy Santhosh, Reuters | 11.27.2024

Aggregated News

Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...

Genomics

A Reading and Discussion with George Estreich

Related Articles

Reproductive Futures: The Promises and Pitfalls of In-Vitro Gametogenesis

Serving Two Masters: Trump Team’s Tensions on Reproductive Politics

An I.V.F. Mix-Up, a Shocking Discovery and an Unbearable Choice

FDA probes blood cancer risk from Bluebird’s gene therapy, weighs regulatory action

Serving Two Masters: Trump Team’s Tensions on Reproductive Politics